On September 17, Philip Morris International (PMI) (NYSE: PM) announced on its official website that its subsidiary Vectura Fertin Pharma, Inc. will sell its subsidiary Vectura Group Ltd. to Molex Asia Holdings Ltd. and enter into a master services agreement to develop Vectura Fertin Pharma's proprietary inhalation therapy drug product line. Vectura will be operated by Phillips Medisize, a subsidiary of Molex.
PMI announced that the sale includes £150 million in upfront cash, subject to customary purchase price adjustments, and could involve deferred payments of up to £148 million. The transaction is subject to standard closing conditions, including regulatory approval.
PMI CEO Jacek Olczak stated that
According to our goals, Vectura enables us to develop a proprietary line of inhalation therapy drug products, and we will continue to focus on long-term innovation in this field.
According to reports, in 2021, PMI acquired Vectura, a British company that manufactures inhalers used to treat lung diseases such as asthma, for over 1 billion pounds.
PMI emphasized that the remaining divisions of Vectura Fertin Pharma will continue to operate independently under PMI ownership and will have a new corporate identity. This business will focus on developing and commercializing oral consumer health and wellness products, as well as inhalable prescription drugs for therapeutic areas such as pain management and cardiovascular emergencies.
Phillips Medisize is a company under Molex that designs and manufactures products for the pharmaceutical and healthcare industries on a global scale.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
